Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Tumor antigen Stories

2010-03-03 11:00:00

DES PLAINES, Ill., March 3 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK. GSK's MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) candidate is currently being evaluated as an adjuvant treatment in melanoma biopsy specimens in the Phase III clinical...

86fb375d9b7810c2b867e5e09ded0a2f1
2009-11-30 14:17:15

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalized vaccines "”produced from healthy and tumor cells from the patient him or herself"” and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumors. The new therapy is administered to participating patients combined with the standard, first-line treatment...

2009-10-29 15:43:05

Helper T cell's effect raises possibility of cellular therapy, vaccine development A specific type of T helper cell awakens the immune system to the stealthy threat of cancer and triggers an attack of killer T cells custom-made to destroy the tumors, scientists from The University of Texas M. D. Anderson Cancer Center report in the early online edition of the journal Immunity. The role of Th17, one of only four known types of T helper cell, opens a possible avenue for overcoming cancer's...

2009-10-21 13:38:50

It was once thought that the two communities of cells within a cancerous breast tumor "“ fast-growing malignant cells and the normal cells that surround them "“ existed independently, without interaction. Then evidence emerged indicating that the normal-looking cells encouraged cells within the tumor to become malignant, but how the one community influenced the other wasn't known. A new study led by Ohio State University cancer researchers published in the Oct. 22 issue of Nature...

2009-07-13 11:26:00

DES PLAINES, Ill., July 13 /PRNewswire-FirstCall/ -- Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop an automated molecular diagnostic test, based on polymerase chain reaction (PCR) technology, intended to screen non-small cell lung cancer (NSCLC) tumors for expression of the MAGE-A3 antigen. GSK's MAGE-A3 ASCI (Antigen Specific Cancer Immunotherapy) candidate is currently being evaluated as an adjuvant treatment in resected NSCLC in the...

2009-07-01 07:15:51

Researchers have identified a protein released by dying brain tumor cells that provides an effective way to gauge the effectiveness of a novel gene therapy treatment for brain cancer. The finding paves the way for a Phase 1 clinical trial expected to begin in late 2009. The two-pronged gene therapy was devised by scientists at the Cedars-Sinai Board of Governors Gene Therapeutics Research Institute.  It uses a harmless, genetically engineered virus to deliver a combination of...

2009-06-18 11:21:02

TAU research uses the Ras protein to fight its own malign effects Oncogenes are genes that when mutated or expressed in high concentrations can cause normal cells to become cancerous. Now research from Tel Aviv University is demonstrating that Ras, one of the first oncogenes discovered, has the power to heal as well as harm. Ph.D. student Oded Rechavi and his fellow researchers at Tel Aviv University's Department of Neurobiology have found that Ras has the ability to transfer from cancer...

2009-06-04 15:30:00

RARITAN, N.J., June 4 /PRNewswire/ -- Ortho Biotech Oncology Research & Development, a unit of Centocor Research & Development, Inc., today announced that it has entered into a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), with Steven A. Rosenberg, M.D., Ph.D., chief, Surgery Branch, serving as the NCI principal investigator, to research and develop novel cell therapy technologies as potential treatments for a variety of...

2009-01-13 09:48:29

New approaches to gene therapy have been found that help eradicate brain tumors and boost the power of the immune system. Researchers at Cedars-Sinai Medical Center in Los Angeles found that HMGB1, a protein released from deteriorating tumor cells, activates dendritic cells and stimulates anti-tumor responses by attaching to an inflammatory receptor known as toll-like receptor 2, TLR2. Evidence shows that toll receptors are responsible for not only recognizing bacterial components, but also...

2009-01-12 19:00:00

U.S. researchers say they used the human genetic code to attract key immune cells into the brain, where they then recognized and attacked tumor cells. The Cedars-Sinai Medical Center researchers in Los Angeles discovered that a protein known as high-mobility group box 1, or HMGB1, released from dying tumor cells activates key immune cells called dendritic cells and stimulates a strong and effective anti-tumor immune response. But the number of dendritic cells in the brain is very small,...